{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:32:47Z","timestamp":1772159567420,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology Technology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.iotech.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T19:12:17Z","timestamp":1568661137000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Immune checkpoints in thymic epithelial tumors: challenges and opportunities"],"prefix":"10.1016","volume":"3","author":[{"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.iotech.2019.09.002_bib1","series-title":"World Health organization classification of tumours of the lung, pleura, thymus and heart","article-title":"WHO histological classification of tumours of the thymus","year":"2015"},{"key":"10.1016\/j.iotech.2019.09.002_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejso.2018.01.078","article-title":"Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting","volume":"45","author":"Imbimbo","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4103\/ijmpo.ijmpo_148_16","article-title":"Utility of Cluster of Differentiation 5 and Cluster of Differentiation 117 Immunoprofile in Distinguishing Thymic Carcinoma from Pulmonary Squamous Cell Carcinoma: A Study on 1800 Nonsmall Cell Lung Cancer Cases","volume":"38","author":"Jha","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib4","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2019.09.002_bib5","series-title":"TNM classification of malignant tumours","article-title":"Thymic tumors","year":"2017"},{"issue":"Suppl 5","key":"10.1016\/j.iotech.2019.09.002_bib6","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","article-title":"Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study","volume":"49","author":"Hishida","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.iotech.2019.09.002_bib8","series-title":"Radiation Oncology","article-title":"Radiation Therapy in Thymoma","author":"Girard","year":"2019"},{"key":"10.1016\/j.iotech.2019.09.002_bib9","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","article-title":"Chemotherapy definitions and policies for thymic malignancies","volume":"6","author":"Girard","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib10","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort","volume":"13","author":"Merveilleux du Vignaux","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.iotech.2019.09.002_bib13","doi-asserted-by":"crossref","first-page":"v595","DOI":"10.1093\/annonc\/mdx391.001","article-title":"Comprehensive Genomic Profiling (CGP) of Thymic Gland Carcinomas","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol"},{"issue":"9 Suppl 2","key":"10.1016\/j.iotech.2019.09.002_bib14","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","article-title":"State of the art of genetic alterations in thymic epithelial tumors","volume":"9","author":"Rajan","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The Integrated Genomic Landscape of Thymic Epithelial Tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.iotech.2019.09.002_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"Bernard","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.iotech.2019.09.002_bib17","first-page":"4","article-title":"B004. OS01.04. Prevalence of autoimmune diseases in thymic epithelial tumors insights from RYTHMIC","author":"Bouchet","year":"2017","journal-title":"Mediastinum"},{"key":"10.1016\/j.iotech.2019.09.002_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jtho.2017.11.118","article-title":"Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database","volume":"13","author":"Padda","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized Trial of Thymectomy in Myasthenia Gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iotech.2019.09.002_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nri1781","article-title":"Journey through the thymus: stromal guides for T-cell development and selection","volume":"6","author":"Takahama","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.iotech.2019.09.002_bib21","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood.V96.12.3872","article-title":"Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease","volume":"96","author":"Hoffacker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.iotech.2019.09.002_bib22","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20171000","article-title":"Redefining thymus medulla specialization for central tolerance","volume":"214","author":"Cosway","year":"2017","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.iotech.2019.09.002_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.immunol.25.022106.141532","volume":"27","author":"Mathis","year":"2009","journal-title":"Aire. Annu Rev Immunol"},{"key":"10.1016\/j.iotech.2019.09.002_bib24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1084\/jem.191.5.891","article-title":"Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice","volume":"191","author":"Nishimura","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.iotech.2019.09.002_bib25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/path.2141","article-title":"Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1)","volume":"211","author":"Str\u00f6bel","year":"2007","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.iotech.2019.09.002_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11864-019-0661-2","article-title":"Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies","volume":"20","author":"Lippner","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1212\/01.CON.0000455873.30438.9b","article-title":"Myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"20","author":"Sanders","year":"2014","journal-title":"Continuum"},{"key":"10.1016\/j.iotech.2019.09.002_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.humpath.2016.09.023","article-title":"PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus","volume":"60","author":"Marchevsky","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.iotech.2019.09.002_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2016.05.007","article-title":"Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy","volume":"99","author":"Katsuya","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.iotech.2019.09.002_bib30","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.iotech.2019.09.002_bib32","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.iotech.2019.09.002_bib33","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1158\/1078-0432.CCR-16-0434","article-title":"Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma","volume":"22","author":"Yokoyama","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2019.09.002_bib34","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/modpathol.2017.6","article-title":"Expression of PD-1 and PD-L1 in thymic epithelial neoplasms","volume":"30","author":"Weissferdt","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.iotech.2019.09.002_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.09.002","article-title":"Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma","volume":"125","author":"Wei","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.iotech.2019.09.002_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.anndiagpath.2018.03.012","article-title":"PD-L1 immuno-expression assay in thymomas: study of 84 cases and review of literature","volume":"34","author":"Guleria","year":"2018","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.iotech.2019.09.002_bib37","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41379-018-0097-4","article-title":"Expression of PD-L1\/PD-1 in lymphoepithelioma-like carcinoma of the thymus","volume":"31","author":"Suster","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.iotech.2019.09.002_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.iotech.2019.09.002_bib39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jclinpath-2017-204788","article-title":"PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus","volume":"71","author":"Bagir","year":"2018","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.iotech.2019.09.002_bib40","doi-asserted-by":"crossref","first-page":"20769","DOI":"10.18632\/oncotarget.25100","article-title":"Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma","volume":"9","author":"Watanabe","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.iotech.2019.09.002_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.athoracsur.2018.08.037","article-title":"Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1","volume":"107","author":"Hakiri","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.iotech.2019.09.002_bib42","article-title":"Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors","author":"Chen","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.iotech.2019.09.002_bib43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/his.13750","article-title":"Heterogeneity of programmed death-ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences","volume":"74","author":"Terra","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.iotech.2019.09.002_bib44","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jtho.2018.04.013","article-title":"Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma","volume":"13","author":"Owen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib45","article-title":"Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors","author":"Bedekovics","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.iotech.2019.09.002_bib46","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/1759-7714.12826","article-title":"Impact of PD-L1, transforming growth factor-\u03b2 expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors","volume":"9","author":"Duan","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.iotech.2019.09.002_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cam4.1943","article-title":"The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma","volume":"8","author":"Funaki","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.iotech.2019.09.002_bib48","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jtho.2016.07.018","article-title":"Response to Pembrolizumab in a Patient with Relapsing Thymoma","volume":"11","author":"Zander","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib49","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1159\/000493187","article-title":"Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression","volume":"11","author":"Isshiki","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib50","first-page":"39","article-title":"The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ~experience of single public hospital in Japan","volume":"26","author":"Uchida","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.iotech.2019.09.002_bib51","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib52","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial","volume":"37","author":"Cho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib53","doi-asserted-by":"crossref","first-page":"78e86","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.iotech.2019.09.002_bib54","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jtho.2016.11.333","article-title":"OA18.03: Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)","volume":"12","author":"Rajan","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib55","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/j.jtho.2018.03.027","article-title":"Mutation Ensemble for Response to Programmed Cell Death 1 Inhibition in Thymic Carcinoma","volume":"13","author":"Lee","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib56","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.iotech.2019.09.002_bib57","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1158\/1078-0432.CCR-18-1449","article-title":"The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2019.09.002_bib58","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/15563650.2017.1401079","article-title":"Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma","volume":"56","author":"Chen","year":"2018","journal-title":"Clin Toxicol (Phila)"}],"container-title":["Immuno-Oncology Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018819300206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018819300206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:39:39Z","timestamp":1762907979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018819300206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":58,"alternative-id":["S2590018819300206"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2019.09.002","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoints in thymic epithelial tumors: challenges and opportunities","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}